The global CAR T-Cell Therapies Market was valued at USD 5.42 billion in 2024 and is projected to reach USD 34.42 billion by 2032, growing at a CAGR of 26.0% during 2025-2032. The market is driven by the transformative potential of CAR-T therapy for hematological malignancies and accelerated research into solid tumors.

Major players in the market include Gilead Sciences, Novartis AG, and Bristol-Myers Squibb. Axicabtagene Ciloleucel (Yescarta) dominated the market in 2024, while Non-Hodgkin Lymphoma led in terms of indication. North America accounted for 63.8% of market revenue in 2024, with the U.S. leading globally.

Recent news includes Bristol entering a capacity reservation agreement with Cellares and Max Healthcare launching CAR-T therapy in Delhi-NCR. Exclusive sections of the report offer insights on clinical pipeline performance, manufacturing capacity benchmarks, patient access analysis, safety outcomes, therapy commercialization, and innovation insights. The market is expected to experience rapid growth in the Asia Pacific region due to increasing research focus and government support. CAR T-cell therapies market is expected to grow at a CAGR of 25.4% from 2021 to 2028, reaching a value of $9.6 billion. The increasing prevalence of cancer and advancements in immunotherapy are driving the market growth. North America holds the largest market share due to high adoption rates and healthcare infrastructure.

SNS Insider, a leading market research agency, provides in-depth analysis and insights into the CAR T-cell therapies market. Their research aims to equip clients with the necessary knowledge to navigate dynamic market conditions. By utilizing surveys, video talks, and focus groups worldwide, they offer accurate market data and consumer opinions for informed decision-making.

Read more at GlobeNewswire: CAR T-Cell Therapies Market Size to Reach 34.42 billion by